S100A11 and metabolic dysfunction-associated steatotic liver disease: Overall, in a diet-induced MASLD/MASH model, targeting hepatic S100A11 emerges as a more effective therapeutic option compared to S100A10, although S100A10 downregulation also showed beneficial effects.